ES2123582T3 - Proteina con capacidad de formacion de huesos y procedimiento para su produccion. - Google Patents

Proteina con capacidad de formacion de huesos y procedimiento para su produccion.

Info

Publication number
ES2123582T3
ES2123582T3 ES93104650T ES93104650T ES2123582T3 ES 2123582 T3 ES2123582 T3 ES 2123582T3 ES 93104650 T ES93104650 T ES 93104650T ES 93104650 T ES93104650 T ES 93104650T ES 2123582 T3 ES2123582 T3 ES 2123582T3
Authority
ES
Spain
Prior art keywords
production
protein
procedure
bone formation
formation capacity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93104650T
Other languages
English (en)
Inventor
Egon Dr Amann
Yoko Otawara-Hamamoto
Reiko Kikuno
Sunao Takeshita
Kenichi Tezuka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HOECHST MARION ROUSSEL Ltd
Sanofi Aventis KK
Original Assignee
HOECHST MARION ROUSSEL Ltd
Nippon Hoechst Marion Roussel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HOECHST MARION ROUSSEL Ltd, Nippon Hoechst Marion Roussel Ltd filed Critical HOECHST MARION ROUSSEL Ltd
Application granted granted Critical
Publication of ES2123582T3 publication Critical patent/ES2123582T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA PRESENTE INVENCION PONE A DISPOSICION LA SECUENCIA DE UNA NUEVA PROTEINA OSF-2 RELACIONADA CON LOS HUESOS QUE PUEDE SER OBTENIDA A PARTIR DE LOS TEJIDOS OSEOS DE LOS MAMIFEROS. LA INVENCION TIENE PREVISTO ADEMAS UN METODO DE PRODUCCION DE OSF-2 MEDIANTE TECNICAS RECOMBINANTES.
ES93104650T 1992-03-27 1993-03-22 Proteina con capacidad de formacion de huesos y procedimiento para su produccion. Expired - Lifetime ES2123582T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP4071501A JPH05268982A (ja) 1992-03-27 1992-03-27 骨形成作用を有する新規な蛋白質およびその製造法

Publications (1)

Publication Number Publication Date
ES2123582T3 true ES2123582T3 (es) 1999-01-16

Family

ID=13462492

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93104650T Expired - Lifetime ES2123582T3 (es) 1992-03-27 1993-03-22 Proteina con capacidad de formacion de huesos y procedimiento para su produccion.

Country Status (9)

Country Link
US (1) US5756664A (es)
EP (1) EP0562508B1 (es)
JP (1) JPH05268982A (es)
AT (1) ATE167232T1 (es)
CA (1) CA2092768A1 (es)
DE (1) DE69319012T2 (es)
DK (1) DK0562508T3 (es)
ES (1) ES2123582T3 (es)
GR (1) GR3027671T3 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011923A1 (en) * 1993-10-29 1995-05-04 Dana-Farber Cancer Institute, Inc. A novel tumor marker and novel method of isolating same
SE520392C2 (sv) 1996-09-27 2003-07-01 Creative Peptides Sweden Ab C Specifika peptider för behandling av diabetes mellitus
JP2002502250A (ja) 1997-05-29 2002-01-22 ボード・オヴ・リージェンツ，ザ・ユニヴァーシティ・オヴ・テキサス・システム Ｏｓｆ２／ｃｂｆａ１組成物および使用の方法
EP1524524A1 (en) * 1998-12-18 2005-04-20 Scios Inc. Methods for detection and use of differentially expressed OSF-2 in diagnosis of cardiac hypertrophy
WO2001057062A1 (en) * 2000-02-03 2001-08-09 Gene Logic, Inc. Modulation of osf-2 in inflammatory and renal diseases
DE60142693D1 (de) * 2000-09-08 2010-09-09 Daiichi Sankyo Co Ltd Arzneimittel für herzversagen
US7087727B2 (en) * 2001-08-13 2006-08-08 Dana-Farber Cancer Institute, Inc. Periostin-based diagnostic assays
CN100348277C (zh) * 2005-08-09 2007-11-14 中国人民解放军第三军医大学 成骨细胞特异性转录因子－2基因修饰的组织工程化骨的构建方法
JP5019464B2 (ja) 2005-12-28 2012-09-05 第一三共株式会社 抗ペリオスチン抗体およびそれを含有するペリオスチンが関与する疾患の予防または治療用医薬組成物
US8017119B2 (en) 2005-12-28 2011-09-13 Daiichi Sankyo Company, Ltd. Antibody against periostin, and a pharmaceutical composition comprising it for preventing or treating a disease in which periostin is involved
JP5238942B2 (ja) 2007-06-27 2013-07-17 国立大学法人大阪大学 ペリオスチンのＥｘｏｎ−１７部位によりコードされるペプチドに対する抗体を含む癌治療剤
JP6161233B2 (ja) * 2008-03-31 2017-07-12 ジェネンテック， インコーポレイテッド 喘息の治療及び診断のための組成物及び方法
US8420310B2 (en) * 2008-06-05 2013-04-16 Saga University Method for detection of idiopathic interstitial pneumonia
JP2012012344A (ja) * 2010-07-01 2012-01-19 Japan Health Science Foundation 創傷治癒剤
EP2652498B1 (en) 2010-12-16 2018-04-18 F.Hoffmann-La Roche Ag Diagnosis and treatments relating to th2 inhibition
JP6183809B2 (ja) 2011-09-06 2017-08-23 株式会社シノテスト ペリオスチンの特定領域に結合する抗体及びこれを用いたペリオスチンの測定方法
JP6218088B2 (ja) 2013-03-08 2017-11-01 国立大学法人大阪大学 ペリオスチンのＥｘｏｎ−２１部位によりコードされるペプチドに対する抗体及び該抗体を含む炎症関連疾患の予防又は治療用医薬組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8078491A (en) * 1990-06-29 1992-01-23 Hoechst Japan Limited Novel protein capable of causing differential growth of cell and production thereof by genetic engineering technology
JPH09200324A (ja) * 1996-01-12 1997-07-31 Ricoh Co Ltd ファクシミリ装置

Also Published As

Publication number Publication date
CA2092768A1 (en) 1993-09-28
JPH05268982A (ja) 1993-10-19
EP0562508B1 (en) 1998-06-10
DK0562508T3 (da) 1999-03-29
EP0562508A2 (en) 1993-09-29
DE69319012D1 (de) 1998-07-16
US5756664A (en) 1998-05-26
ATE167232T1 (de) 1998-06-15
GR3027671T3 (en) 1998-11-30
DE69319012T2 (de) 1998-12-17
EP0562508A3 (en) 1994-06-22

Similar Documents

Publication Publication Date Title
DE3884529D1 (de) Leader-anteile zur produktion von rekombinanten proteinen.
DE3772121D1 (de) Abtastendoskop zur chirurgischen verwendung.
DK0457430T3 (da) Kollagenkonstruktioner
DE3856433D1 (de) Triazolin(thi)on Zwischenprodukte zur Herstellung von Herbiziden
ES533924A0 (es) Procedimiento para preparar proteina de uroquinasa humana bioactiva
DE69326559D1 (de) Rekombinante methode und wirt zur herstellung von xylitol
DE69308664D1 (de) Verfahren zur Herstellung von Silikonemulsionen
GR3027671T3 (en) Protein with bone formation ability and process for its production
DE69502384D1 (de) Prozess zur herstellung von polyarylenetherketonen
DE59003282D1 (de) Verfahren zur Herstellung von Dawsonit.
DE59300418D1 (de) Verfahren zur Herstellung von natürlichen Antioxidantien.
DE69010294D1 (de) Verwendung von Antiprogestomimetika zur Stimulierung des Eisprungs.
DE69530176D1 (de) Verfahren zur Herstellung von Protein
ATE107935T1 (de) Verfahren zur herstellung von propylen-ethylen- copolymerisaten.
DE69313863D1 (de) Verfahren zur herstellung von sulfonaten
DE59004279D1 (de) Verfahren zur C-terminalen Modifizierung von Proteinen.
DE69408394D1 (de) 4-Piperidino-piperidin zur Behandlung von Tumoren
DE3884324D1 (de) Verfahren zur Herstellung von menschlichen pro-apolipoprotein-A-I-ähnlichen Proteinen.
FI884652L (fi) Menetelmä t-PA-kaltaisten proteiinien tuotannon tehostamiseksi
DE69014042D1 (de) Verfahren zur Herstellung von menschlichem Osteocalcin.
DE3886367D1 (de) Verwendung von Antigestagenen zur Herstellung von Arzneimitteln.
DE69707910D1 (de) Prozess zur Herstellung von Dimethylpropylamin
DE69018050D1 (de) Verfahren zur Stabilisierung von Percarbonsäuren.
DE3888216D1 (de) Methode zur Herstellung von aminokohlenwasserstoff-substituierten Ketoximosilanen.
DE69007028D1 (de) Verfahren zur Herstellung von 3,4-Epoxybutyrat und Zwischenprodukte dafür.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 562508

Country of ref document: ES